Código QR (código de barras bidimensional)

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

ObjectiveADAPT+ assessed the long-term safety, tolerability, and efficacy of efgartigimod in adult participants with generalized myasthenia gravis (gMG).MethodsADAPT+ was an open-label, single-arm, multicenter, up to 3-year extension of the pivotal phase 3 ADAPT study. Efgartigimod was administered...

ver descrição completa

Na minha lista:
Principais autores: James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study Group
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-01-01
coleção:Frontiers in Neurology
Assuntos:
efgartigimod
myasthenia gravis
neonatal Fc receptor
FcRn
IgG recycling
antibody fragment
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fneur.2023.1284444/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados